Allergan (AGN) says Darpin data does not support Phase 3 trials.
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
UPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Ionis Pharma's therapy to treat rare genetic disorder
- Fed's Hammack on LinkedIn: 'Right now, what I'm hearing is that it's time to act'
- Nscale Seeking $3.5 Billion in Pre-IPO Financing - Bloomberg
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
